Cite
Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis
MLA
Enqiang Qin, et al. “Nucleoside Analogs Treatment Delay the Onset of Hepatocellular Carcinoma in Patients with HBV-Related Cirrhosis.” Oncotarget, vol. 8, no. 57, Apr. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c2bc8d15dedf82e0cfcc59ddaef25a5d&authtype=sso&custid=ns315887.
APA
Enqiang Qin, Zengmin Liu, Zheng Zhang, Yanwei Zhong, Li Shuo, Zhenman Wei, Bi Jingfeng, Jun Hou, & Shuiwen Liu. (2017). Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis. Oncotarget, 8(57).
Chicago
Enqiang Qin, Zengmin Liu, Zheng Zhang, Yanwei Zhong, Li Shuo, Zhenman Wei, Bi Jingfeng, Jun Hou, and Shuiwen Liu. 2017. “Nucleoside Analogs Treatment Delay the Onset of Hepatocellular Carcinoma in Patients with HBV-Related Cirrhosis.” Oncotarget 8 (57). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c2bc8d15dedf82e0cfcc59ddaef25a5d&authtype=sso&custid=ns315887.